세계의 철제 정맥내 투여 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 제품별, 용도별, 지역별, 부문 예측(2024-2030년)

Intravenous Iron Drugs Market Size, Share & Trends Analysis Report By Product (Iron Sucrose, Iron Dextran, Ferric Carboxymaltose), By Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,194,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,571,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,325,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

철제 정맥내 투여 시장의 성장 및 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 철제 정맥내 투여 시장 규모는 2024년부터 2030년까지 CAGR 9.2%로 확대될 전망이며, 2030년에는 56억 2,000만 달러에 이를 전망입니다.

예측 기간 동안 업계 경쟁은 더 높은 수준으로 유지될 것으로 예상됩니다. 이 시장은 수익 점유율의 대부분을 세계 기업이 차지하고 있습니다. 게다가 성장 기회는 새로운 진출기업을 유치하고 경쟁 기업간 경쟁 관계를 더욱 강화하고 있습니다. 시장은 세분화되고 있으며, 대기업은 보다 큰 점유율을 얻기 위해 전략적 제휴, 인수, 신약 출시 등 광범위한 성장 전략을 채택하고 있습니다.

감염으로 인한 높은 질병 부담은 영양 불량과 함께 이 지역 소아 빈혈의 주요 원인 중 하나입니다. 신형 코로나 바이러스의 대유행은 심각한 환자의 빈혈을 증가시키고 때로는 저산소증을 유발했습니다. 이 때문에 세계의 빈혈 치료용 철제 수요가 더욱 높아졌습니다.

빈혈의 유병률 증가는 다양한 부인과 및 소화기 질환에 기인하며 세계의 정맥 내 치료 보급을 촉진하고 있습니다. 예를 들어, 빈혈의 전반적인 유병률은 비임신 여성의 경우 29.6%, 같은 연령대의 임신 여성의 경우 36.5%입니다. 의료 예산 증가와 투자 증가로 시장은 예측 기간 동안 크게 성장할 것으로 예상됩니다.

경구 철제의 단점인 위통, 변비, 식욕 부진, 메스꺼움, 구토 등 소화기계의 문제는 환자가 정맥 주사제를 선호하는 이유가 되고 있습니다. 철제 정맥내 투여는 체내로의 철 흡수를 증가시키고, 적혈구 조혈 자극 인자(ESA)의 작용을 촉진하며, 빈혈 상태를 개선하는 것으로 나타났습니다. 다른 장점은 심장 건강을 유지하는 것, 투석 환자, 특히 혈액 투석을 받은 환자가 사용할 수 있다는 것입니다.

철제 정맥내 투여 시장 보고서 하이라이트

• 카르복시 말토스 철은 용도 증가 및 부작용의 적음과 맞물려 우수한 성능과 비용 절감으로 2023년에 철제 정맥내 투여 산업을 지배하였습니다.
• 수크로스 철은 2023년 시장에서 큰 점유율을 차지했습니다. 심각한 알레르기 반응의 발생률이 낮다는 것은 이러한 약물의 채용률을 높이고 있습니다.
• CKD와 CKD 관련 철 결핍성 빈혈 사례의 유병률이 증가함에 따라 만성 신장병 부문이 2023년에 가장 큰 점유율을 차지했습니다.
• 북미는 점적약에 대한 높은 수요 및 소화기 질환, 암, CKD의 유병률 증가로 2023년 최대 지역 점유율을 차지했습니다.
• 아시아태평양은 미충족 요구 증가, 의료비 증가, 정평 있는 세계 기업의 현지 진출을 배경으로 추정 및 예측 기간 중에 가장 급성장할 것으로 보입니다.
• 주요 진출기업은 AbbVie Inc., AMAG Pharmaceuticals(Covis Pharma), Daiichi Sankyo Company, Ltd., Sanofi, Vifor Pharma Management Ltd.(CSL), PHARMAC, Pharmaceuticals Inc.(CSL), PHARMACOSMOS A/S, Zydus Group 등입니다.

목차

제1장 조사 방법 및 범위

제2장 주요 요약

제3장 철제 정맥내 투여 시장 : 산업 전망

• 시장 계통의 전망
• 시장 역학
• Porter's Five Forces 분석
• PESTLE 분석
• COVID-19의 영향 분석

제4장 철제 정맥내 투여 시장-부문 분석 : 제품별(100만 달러)(2018-2030년)

• 철제 정맥내 투여 시장 : 제품별 변동 분석
• 제품별
  • 철 덱스트란
  • 철 수크로스
  • 카르복시말토스철
  • 기타

제5장 철제 정맥내 투여 시장-부문 분석 : 용도별(100만 달러)(2018-2030년)

• 철제 정맥내 투여 시장 : 용도별 변동 분석
• 용도별

제6장 철제 정맥내 투여 시장 : 지역별 추정 및 동향 분석

• 철제 정맥내 투여 시장 : 지역별 전망
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제7장 경쟁 구도

• 기업 분류
• 전략 매핑
  • 신제품 발매
  • 파트너십
  • 취득
  • 콜라보레이션
  • 자금조달
• 주요 기업의 시장 점유율 분석(2022년)
• 기업 프로파일
  • Allergan, Inc.
  • AMAG Pharmaceuticals. Inc.
  • Daiichi Sankyo Company, Ltd.
  • Sanofi
  • Fresenius Medical Care AG &Co.
  • Vifor Pharma Management Ltd.
  • Pharmacosmos A/S
  • Rockwell Medical, Inc.

제8장 결론

AJY

영문 목차

영문목차

Intravenous Iron Drugs Market Growth & Trends:

The global intravenous iron drugs market size is expected to reach USD 5.62 billion by 2030, expanding at a CAGR of 9.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. Industry rivalry is expected to remain at a higher level over the forecast period. The market is dominated by global players accounting for most of the revenue share. Moreover, growing opportunities attract new players, which further augments the competitive rivalry. The market is fragmented and major players are involved in adopting extensive growth strategies such as entering strategic alliances, acquisitions, and new drug launches to capture a larger share.

The high disease burden of infectious diseases, coupled with poor nutrition, is one of the major causes of anemia among children in this region. The novel coronavirus pandemic has also increased anemia in severely affected patients, causing hypoxia in some cases. This has further increased the demand for intravenous iron drugs for the treatment of anemia across the globe.

The increase in the prevalence of anemia can also be attributed to various gynecological and gastrointestinal disorders, facilitating an increasing uptake of IV treatment globally. For instance, the overall prevalence of anemia is 29.6% in nonpregnant women and 36.5% in pregnant women of the same age group. With growing healthcare budgets and increasing investment, the market is anticipated to grow significantly during the forecast period.

Drawbacks of oral iron drugs such as digestive problems such as stomach aches, constipation, loss of appetite, nausea, and vomiting are reasons for patients to prefer intravenous drugs. The use of intravenous iron drugs has been shown to bring about increased iron adoption by the body, facilitating Erythropoiesis-stimulating Agents (ESAs) to function in an enhanced manner to improve the anemic condition. Other advantages are the preservation of heart health and the ability to be used by dialysis patients, especially those undergoing hemodialysis.

Intravenous Iron Drugs Market Report Highlights:

• Ferric carboxymaltose dominated the intravenous iron drugs industry in 2023 due to its increasing application, superior performance coupled with fewer adverse effects, and reduced cost
• Iron sucrose held a significant share of the market in 2023. A low rate of severe allergic reactions has increased the adoption rate of these drugs
• The chronic kidney disease segment held the largest share in 2023, due to the increasing prevalence of CKD and CKD-associated iron deficiency anemia cases
• North America held the largest regional share in 2023 due to the high demand for intravenous drugs and the increasing prevalence of GI disorders, cancer, and CKD
• Asia Pacific is estimated to exhibit the fastest growth over the forecast period attributed to growing unmet patient needs, increasing healthcare expenditure, and the local presence of established global players
• Key players include AbbVie Inc.; AMAG Pharmaceuticals (Covis Pharma); Daiichi Sankyo Company, Ltd.; Sanofi; Vifor Pharma Management Ltd. (CSL); PHARMACOSMOS A/S; Zydus Group

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation & Scope
  • 1.1.1 Regional Scope
  • 1.1.2 Market Definitions
  • 1.1.3 Estimates and Forecast Timeline
• 1.2 Objectives
  • 1.2.1 Objective - 1
  • 1.2.2 Objective - 2
  • 1.2.3 Objective - 3
• 1.3 Research Methodology
• 1.4 Information Procurement
  • 1.4.1 Purchased Database
  • 1.4.2 GVR's Internal Database
  • 1.4.3 Secondary Sources
  • 1.4.4 Primary research
  • 1.4.5 Sample size for the study on Intravenous Iron Drugs Market:
• 1.5 Information or Data Analysis
  • 1.5.1 Data Analysis Models
• 1.6 Market Formulation and Validation
• 1.7 Market Model
  • 1.7.1 Market study, by Company Market Share
  • 1.7.2 Commodity Flow Analysis
    • 1.7.2.1 Approach 1: Commodity Flow Approach
    • 1.7.2.2 Approach 2: Country Wise Market Estimation Using Bottom-up Approach
  • 1.7.3 Regional analysis
• 1.8 Research Assumptions
• 1.9 List of Secondary Sources
• 1.10 List of Abbreviations

Chapter 2 EXECUTIVE SUMMARY

• 2.1 Market Snapshot, 2023
• 2.2 Segment Snapshot
• 2.3 Competitive Snapshot

Chapter 3 Intravenous Iron Drugs Market - Industry Outlook

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market
  • 3.1.2 Related/Ancillary Market Outlook
    • 3.1.2.1 Inflammatory Bowel Disease Treatment Market
    • 3.1.2.2 Anemia Treatment Market
• 3.2 Market Dynamics
  • 3.2.1 Market Drivers
    • 3.2.1.1 Increasing prevalence of target diseases
    • 3.2.1.2 Rising prevalence of iron deficiency anemia
    • 3.2.1.3 Advantages of intravenous iron drugs
  • 3.2.2 Market Restraint Analysis
    • 3.2.2.1 Adverse effects associated with iron drugs
    • 3.2.2.2 Increasing approvals of oral iron drugs
• 3.3 PORTER'S Five Forces Analysis
• 3.4 PESTLE Analysis
• 3.5 COVID-19 Impact Analysis

Chapter 4 Intravenous Iron Drugs Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)

• 4.1 Intravenous Iron Drugs Market: Product Movement Analysis
• 4.2 Intravenous Iron Drugs Market Estimates & Forecast, by Product (USD Million)
  • 4.2.1 Iron Dextran
  • 4.2.2 Iron Sucrose
  • 4.2.3 Ferric Carboxymaltose
  • 4.2.4 Others

Chapter 5 Intravenous Iron Drugs Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)

• 5.1 Intravenous Iron Drugs Market: Application Movement Analysis
• 5.2 Intravenous Iron Drugs Market Estimates & Forecast, by Application (USD Million)
  • 5.2.1 Chronic Kidney Disease
  • 5.2.2 Inflammatory Bowel Disease
  • 5.2.3 Cancer
  • 5.2.4 Other Diseases

Chapter 6 Intravenous Iron Drugs Market: Regional Estimates and Trend Analysis

• 6.1 Intravenous Iron Drugs Market: Regional Outlook
• 6.2 North America
  • 6.2.1 North America Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.2.2 U.S.
    • 6.2.2.1 Key Country Dynamics
    • 6.2.2.2 U.S. Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2.3 Target Disease Prevalence
    • 6.2.2.4 Market & Competitive Scenario
    • 6.2.2.5 Regulatory Framework
    • 6.2.2.6 Reimbursement Scenario
  • 6.2.3 Canada
    • 6.2.3.1 Key Country Dynamics
    • 6.2.3.2 Canada Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3.3 Target Disease Prevalence
    • 6.2.3.4 Market & Competitive Scenario
    • 6.2.3.5 Regulatory Framework
    • 6.2.3.6 Reimbursement Scenario
• 6.3 Europe
  • 6.3.1 Europe Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.3.2 UK
    • 6.3.2.1 Key Country Dynamics
    • 6.3.2.2 UK Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2.3 Target Disease Prevalence
    • 6.3.2.4 Market & Competitive Scenario
    • 6.3.2.5 Regulatory Framework
    • 6.3.2.6 Reimbursement Scenario
  • 6.3.3 Germany
    • 6.3.3.1 Key Country Dynamics
    • 6.3.3.2 Germany Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3.3 Target Disease Prevalence
    • 6.3.3.4 Market & Competitive Scenario
    • 6.3.3.5 Regulatory Framework
    • 6.3.3.6 Reimbursement Scenario
  • 6.3.4 France
    • 6.3.4.1 Key Country Dynamics
    • 6.3.4.2 France Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4.3 Target Disease Prevalence
    • 6.3.4.4 Market & Competitive Scenario
    • 6.3.4.5 Regulatory Framework
    • 6.3.4.6 Reimbursement Scenario
  • 6.3.5 Italy
    • 6.3.5.1 Key Country Dynamics
    • 6.3.5.2 Italy Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5.3 Target Disease Prevalence
    • 6.3.5.4 Market & Competitive Scenario
    • 6.3.5.5 Regulatory Framework
    • 6.3.5.6 Reimbursement Scenario
  • 6.3.6 Spain
    • 6.3.6.1 Key Country Dynamics
    • 6.3.6.2 Spain Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6.3 Target Disease Prevalence
    • 6.3.6.4 Market & Competitive Scenario
    • 6.3.6.5 Regulatory Framework
    • 6.3.6.6 Reimbursement Scenario
  • 6.3.7 Denmark
    • 6.3.7.1 Key Country Dynamics
    • 6.3.7.2 Denmark Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7.3 Target Disease Prevalence
    • 6.3.7.4 Market & Competitive Scenario
    • 6.3.7.5 Regulatory Framework
    • 6.3.7.6 Reimbursement Scenario
  • 6.3.8 Sweden
    • 6.3.8.1 Key Country Dynamics
    • 6.3.8.2 Sweden Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8.3 Target Disease Prevalence
    • 6.3.8.4 Market & Competitive Scenario
    • 6.3.8.5 Regulatory Framework
    • 6.3.8.6 Reimbursement Scenario
  • 6.3.9 Norway
    • 6.3.9.1 Key Country Dynamics
    • 6.3.9.2 Norway Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9.3 Target Disease Prevalence
    • 6.3.9.4 Market & Competitive Scenario
    • 6.3.9.5 Regulatory Framework
    • 6.3.9.6 Reimbursement Scenario
    • 6.3.9.7 Rest of Europe Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)s
• 6.4 Asia Pacific
  • 6.4.1 Asia Pacific Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2 Japan
    • 6.4.2.1 Key Country Dynamics
    • 6.4.2.2 Japan Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2.3 Target Disease Prevalence
    • 6.4.2.4 Market & Competitive Scenario
    • 6.4.2.5 Regulatory Framework
    • 6.4.2.6 Reimbursement Scenario
  • 6.4.3 China
    • 6.4.3.1 Key Country Dynamics
    • 6.4.3.2 China Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3.3 Target Disease Prevalence
    • 6.4.3.4 Market & Competitive Scenario
    • 6.4.3.5 Regulatory Framework
    • 6.4.3.6 Reimbursement Scenario
  • 6.4.4 India
    • 6.4.4.1 Key Country Dynamics
    • 6.4.4.2 India Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4.3 Target Disease Prevalence
    • 6.4.4.4 Market & Competitive Scenario
    • 6.4.4.5 Regulatory Framework
    • 6.4.4.6 Reimbursement Scenario
  • 6.4.5 Australia
    • 6.4.5.1 Key Country Dynamics
    • 6.4.5.2 Australia Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5.3 Target Disease Prevalence
    • 6.4.5.4 Market & Competitive Scenario
    • 6.4.5.5 Regulatory Framework & Reimbursement Scenario
  • 6.4.6 Thailand
    • 6.4.6.1 Key Country Dynamics
    • 6.4.6.2 Thailand Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6.3 Target Disease Prevalence
    • 6.4.6.4 Market & Competitive Scenario
    • 6.4.6.5 Regulatory Framework
    • 6.4.6.6 Reimbursement Scenario
  • 6.4.7 South Korea
    • 6.4.7.1 Key Country Dynamics
    • 6.4.7.2 South Korea Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7.3 Target Disease Prevalence
    • 6.4.7.4 Market & Competitive Scenario
    • 6.4.7.5 Regulatory Framework/Reimbursement Scenario
    • 6.4.7.6 Rest of Asia Pacific Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.5 Latin America
  • 6.5.1 Latin America Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2 Brazil
    • 6.5.2.1 Key Country Dynamics
    • 6.5.2.2 Brazil Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2.3 Target Disease Prevalence
    • 6.5.2.4 Market & Competitive Scenario
    • 6.5.2.5 Regulatory Framework
    • 6.5.2.6 Reimbursement Scenario
  • 6.5.3 Mexico
    • 6.5.3.1 Key Country Dynamics
    • 6.5.3.2 Mexico Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3.3 Target Disease Prevalence
    • 6.5.3.4 Market & Competitive Scenario
    • 6.5.3.5 Regulatory Framework
    • 6.5.3.6 Reimbursement Scenario
  • 6.5.4 Argentina
    • 6.5.4.1 Key Country Dynamics
    • 6.5.4.2 Argentina Intravenous Iron Drugs Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.4.3 Target Disease Prevalence
    • 6.5.4.4 Market & Competitive Scenario
    • 6.5.4.5 Regulatory Framework
    • 6.5.4.6 Reimbursement Scenario
    • 6.5.4.7 Rest of Latin America Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.6 MEA
  • 6.6.1 MEA Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million
  • 6.6.2 South Africa
    • 6.6.2.1 Key Country Dynamics
    • 6.6.2.2 South Africa Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2.3 Target Disease Prevalence
    • 6.6.2.4 Market & Competitive Scenario
    • 6.6.2.5 Regulatory Framework
    • 6.6.2.6 Reimbursement Scenario
  • 6.6.3 Saudi Arabia
    • 6.6.3.1 Key Country Dynamics
    • 6.6.3.2 Saudi Arabia Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3.3 Target Disease Prevalence
    • 6.6.3.4 Market & Competitive Scenario
    • 6.6.3.5 Regulatory Framework
    • 6.6.3.6 Reimbursement Scenario
  • 6.6.4 UAE
    • 6.6.4.1 Key Country Dynamics
    • 6.6.4.2 UAE Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4.3 Target Disease Prevalence
    • 6.6.4.4 Market & Competitive Scenario
    • 6.6.4.5 Regulatory Framework
    • 6.6.4.6 Reimbursement Scenario
  • 6.6.5 Kuwait
    • 6.6.5.1 Key Country Dynamics
    • 6.6.5.2 Kuwait Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5.3 Target Disease Prevalence
    • 6.6.5.4 Market & Competitive Scenario
    • 6.6.5.5 Regulatory Framework
    • 6.6.5.6 Reimbursement Scenario
    • 6.6.5.7 Rest of MEA Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7 Competitive Landscape

• 7.1 Company Categorization
• 7.2 Strategy Mapping
  • 7.2.1 New Product Launch
  • 7.2.2 Partnerships
  • 7.2.3 Acquisition
  • 7.2.4 Collaboration
  • 7.2.5 Funding
• 7.3 Key Company Market Share Analysis, 2022
• 7.4 Company Profiles
  • 7.1.1 Allergan, Inc.
    • 7.1.1.1 Company overview
    • 7.1.1.2 Financial performance
    • 7.1.1.3 Product benchmarking
    • 7.1.1.4 Strategic initiatives
  • 7.1.2 AMAG Pharmaceuticals. Inc.
    • 7.1.2.1 Company overview
    • 7.1.2.2 Financial performance
    • 7.1.2.3 Product benchmarking
    • 7.1.2.4 Strategic initiatives
  • 7.1.3 Daiichi Sankyo Company, Ltd.
    • 7.1.3.1 Company overview
    • 7.1.3.2 Financial performance
    • 7.1.3.3 Product benchmarking
    • 7.1.3.4 Strategic initiatives
  • 7.1.4 Sanofi
    • 7.1.4.1 Company overview
    • 7.1.4.2 Financial performance
    • 7.1.4.3 Product benchmarking
    • 7.1.4.4 Strategic initiatives
  • 7.1.5 Fresenius Medical Care AG & Co.
    • 7.1.5.1 Company overview
    • 7.1.5.2 Financial performance
    • 7.1.5.3 Product benchmarking
    • 7.1.5.4 Strategic initiatives
  • 7.1.6 Vifor Pharma Management Ltd.
    • 7.1.6.1 Company overview
    • 7.1.6.2 Financial performance
    • 7.1.6.3 Product benchmarking
    • 7.1.6.4 Strategic initiatives
  • 7.1.7 Pharmacosmos A/S
    • 7.1.7.1 Company overview
    • 7.1.7.2 Financial performance
    • 7.1.7.3 Product benchmarking
    • 7.1.7.4 Strategic initiatives
  • 7.1.8 Rockwell Medical, Inc.
    • 7.1.7.1 Company overview
    • 7.1.7.2 Financial performance
    • 7.1.7.3 Product benchmarking
    • 7.1.7.4 Strategic initiatives

Chapter 8 Conclusion

관련자료